{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:44:30Z","timestamp":1794113070980,"version":"4.8.0"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Cure Huntington\u2019s Disease Initiative (CHDI)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The purpose of this study was to inform the design of randomized clinical trials in early\u2010stage manifest Huntington's disease through analysis of longitudinal data from TRACK\u2010Huntington's Disease (TRACK\u2010HD), a multicenter observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compute sample sizes required for trials with candidate clinical, functional, and imaging outcomes, whose aims are to reduce rates of change. The calculations use a 2\u2010stage approach: first using linear mixed models to estimate mean rates of change and components of variability from TRACK\u2010HD data and second using these to predict sample sizes for a range of trial designs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For each outcome, the primary drivers of the required sample size were the anticipated treatment effect and the duration of treatment. Extending durations from 1 to 2 years yielded large sample size reductions. Including interim visits and incorporating stratified randomization on predictors of outcome together with covariate adjustment gave more modest, but nontrivial, benefits. Caudate atrophy, expressed as a percentage of its baseline, was the outcome that gave smallest required sample sizes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Here we consider potential required sample sizes for clinical trials estimated from naturalistic observation of longitudinal change. Choice among outcome measures for a trial must additionally consider their relevance to patients and the expected effect of the treatment under study. For all outcomes considered, our results provide compelling arguments for 2\u2010year trials, and we also demonstrate the benefits of incorporating stratified randomization coupled with covariate adjustment, particularly for trials with caudate atrophy as the primary outcome. The benefits of enrichment are more debatable, with statistical benefits offset by potential recruitment difficulties and reduced generalizability. \u00a9 2017 International Parkinson and Movement Disorder Society<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.27122","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T07:06:40Z","timestamp":1505372800000},"page":"1610-1619","source":"Crossref","is-referenced-by-count":15,"title":["Design optimization for clinical trials in early\u2010stage manifest Huntington's disease"],"prefix":"10.1002","volume":"32","author":[{"given":"Chris","family":"Frost","sequence":"first","affiliation":[{"name":"Department of Medical Statistics London School of Hygiene and Tropical Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Mulick","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics London School of Hygiene and Tropical Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael I.","family":"Scahill","sequence":"additional","affiliation":[{"name":"Huntington's Disease Centre, UCL Institute of Neurology Department of Neurodegenerative Disease, University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Owen","sequence":"additional","affiliation":[{"name":"Huntington's Disease Centre, UCL Institute of Neurology Department of Neurodegenerative Disease, University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Aylward","sequence":"additional","affiliation":[{"name":"Center for Integrative Brain Research Seattle Children's Research Institute Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics University of British Columbia Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Durr","sequence":"additional","affiliation":[{"name":"Brain and Spine Institute, INSERM U1127, Centre National de la Recherche Scientifique, UMR7225 Sorbonne Universit\u00e9s, University Pierre and Marie Curie, Paris VI UMR_S1127 Paris France"},{"name":"Assistance Publique \u2010 H\u00f4pitaux de Paris, Genetic Department Piti\u00e9 \u2010Salp\u00eatri\u00e8re University Hospital Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymund A. C.","family":"Roos","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Centre Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Borowsky","sequence":"additional","affiliation":[{"name":"CHDI Management, CHDI Foundation Princeton New Jersey USA"},{"name":"Clinical Development, Neurodegenerative Diseases Teva Pharmaceuticals Malvern Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Stout","sequence":"additional","affiliation":[{"name":"School of Psychological Sciences Monash University Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Reilmann","sequence":"additional","affiliation":[{"name":"George Huntington Institute Muenster Germany"},{"name":"Institute for Clinical Radiology University of Muenster Muenster Germany"},{"name":"Department of Neurodegenerative Diseases and Hertie\u2010Institute for Clinical Brain Research University of Tuebingen Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Langbehn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Iowa Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[{"name":"Huntington's Disease Centre, UCL Institute of Neurology Department of Neurodegenerative Disease, University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[{"name":"CHDI Management, CHDI Foundation Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the TRACK\u2010HD Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"issue":"3","key":"e_1_2_8_2_1","first-page":"CD006456","article-title":"Therapeutic interventions for disease progression in Huntington's disease","author":"Mestre T","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26021"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.523"},{"key":"e_1_2_8_5_1","unstructured":"Critical Path Institute.U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute's Clinical Trial Simulation Tool for Alzheimer's Disease.2013 consulted December 2014.http:\/\/c\u2010path.org\/wp\u2010content\/uploads\/2014\/03\/US\u2010FDA\u2010EMA\u2010agency\u2010reach\u2010landmark\u2010decisions\u2010C\u2010Path\u2010clinical\u2010trial\u2010simulation\u2010tool\u2010for\u2010alzheimers\u2010disease.pdf"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70170-X"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70276-3"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70263-0"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70088-7"},{"key":"e_1_2_8_10_1","volume-title":"Linear Mixed Models for Longitudinal Data","author":"Verbeke G","year":"2000"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25663"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182020123"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1109\/42.640753"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.208264"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3280"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0173-4"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1296"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21181"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo\u2010controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","author":"The Huntington Study Group","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003478"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2015.07.087"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-0062"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410521"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1909"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000167542.89697.0f"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9"},{"key":"e_1_2_8_28_1","first-page":"667","article-title":"Analyzing laboratory marker changes in AIDS clinical trials","volume":"4","author":"Dawson JD","year":"1991","journal-title":"J AIDS"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2307\/2532244"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000169025.09670.6d"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.12.1771"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62242-4"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2307\/2529712"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07458.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159743.08996.99"},{"key":"e_1_2_8_36_1","volume-title":"Huntington's Disease","author":"Borowsky B","year":"2014"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.07.009"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.27122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.27122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:53:55Z","timestamp":1760964835000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.27122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/mds.27122"],"URL":"https:\/\/doi.org\/10.1002\/mds.27122","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}